Regis A. Vilchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Regis A. Vilchez has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Campbell
AbbVie, Inc., North Chicago, IL 60064, USA
1 shared publication - Bryan R. Cobb
Roche Molecular Systems Inc., Pleasanton, California, USA
1 shared publication - Eric Lawitz
Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas, USA
1 shared publication - Fred Poordad
The Texas Liver Institute, University of Texas Health, San Antonio, TX, USA
1 shared publication - Gabrielle Heilek
Roche Sequencing Solutions, Pleasanton, California
1 shared publication - James G. Sullivan
Parkway Medical, Birmingham, Alabama
1 shared publication
Latest Publications
- Open Access
- 19 September 2014
- Published by Elsevier in Journal of Infection
- Vol. 70 (2) , 197-205
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
- 19 September 2014
- Published by Elsevier in Journal of Infection
- Vol. 70 (2) , 197-205
Open AccessExploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
- Open Access
- 5 September 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S5) , S8
Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
Molecular tests that detect and/or quantify HCV RNA are important in the diagnosis and management of patients with chronic hepatitis C (CHC) undergoing anti-viral therapy. The primary goal of anti-HCV therapy is to achieve a sustained virologic response (SVR) defined as "undetectable" Hepatitis C Virus (HCV) RNA in the serum or plasma at 12 to 24 weeks following the end of treatment.
- 5 September 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S5) , S8
Open AccessMolecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
Molecular tests that detect and/or quantify HCV RNA are important in the diagnosis and management of patients with chronic hepatitis C (CHC) undergoing anti-viral therapy. The primary goal of anti-HCV therapy is to achieve a sustained virologic response (SVR) defined as "undetectable" Hepatitis C Virus (HCV) RNA in the serum or plasma at 12 to 24 weeks following the end of treatment.